CN110624102A - Clinical application of bevacizine as medicine for repairing demodex disease skin damage - Google Patents
Clinical application of bevacizine as medicine for repairing demodex disease skin damage Download PDFInfo
- Publication number
- CN110624102A CN110624102A CN201911086633.8A CN201911086633A CN110624102A CN 110624102 A CN110624102 A CN 110624102A CN 201911086633 A CN201911086633 A CN 201911086633A CN 110624102 A CN110624102 A CN 110624102A
- Authority
- CN
- China
- Prior art keywords
- demodex
- growth factor
- fibroblast growth
- repair
- basic fibroblast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an application of shellfish refreshment in clinic as a medicine for repairing demodex disease skin damage. Clinical cases prove that the recombinant bovine basic fibroblast growth factor gel can obviously repair skin inflammation symptoms of the demodex disease, such as erythema, pimple and the like, can obviously inhibit and smooth nodules caused by inflammatory granuloma tissues in the dermis layer of the demodex disease, and can smooth and eliminate skin damage erythema and pimple of a patient with the demodex disease after repair and smooth and improve the nodules formed by the inflammatory granuloma. And (3) clinical trial verification: the recombinant bovine basic fibroblast growth factor gel is used as a medicine for repairing demodex diseases, has good curative effect and high safety, is easily accepted by patients, and relieves the physical and psychological pain of the patients. Opens up a new treatment way for the recombinant bovine basic fibroblast growth factor gel.
Description
Technical Field
The invention belongs to the field of medicines, and relates to a new application of a recombinant bovine basic fibroblast growth factor gel, in particular to an application of the recombinant bovine basic fibroblast growth factor gel in clinic as a medicine for repairing demodex disease skin damage.
Background
Recombinant bovine basic fibroblast growth factor gel (rbFGF) is sold as Beixin (Zhuhaisheng Sheng biological pharmacy Co., Ltd.), and belongs to fibroblast growth factor medicines (see figure 1). At present, the recombinant bovine basic fibroblast growth factor is mainly applied to wound repair, such as burn wounds (including superficial II degree and deep II degree), chronic wound treatment (including body surface chronic ulcer) and fresh wounds (including trauma, donor area wounds, operation wounds and the like) and treatment of corneal injury repair, but the application of the recombinant bovine basic fibroblast growth factor to repair of demodex diseases is not reported.
Demodex mite disease (A)Demodicosis) The common parasitic infectious diseases mainly comprising hair follicle sebaceous gland units of the head, the face and the chest and the back, which are caused by human Demodex mites, are only two kinds of parasitic diseases of the human body, namely the hair follicle Demodex mites and the sebaceous Demodex mites. Demodex has been found to be common in the following skin disorders: cutaneous pruritus with or without erythema, hairless or persistent telangiectasia, seborrheic dermatitis, papulopustular rash on the face, scalp or chest and back, perioral dermatitis, hormone-dependent dermatitis, and skin lesions in patients with chemotherapy-induced immunosuppression or AIDS. The demodex disease has various expression forms, but the main expression form is inflammatory erythema infiltration on the face, neck and chest and back, pimples higher than the skin surface can also appear on the basis of the erythema, and nodules formed by inflammatory granuloma tissues can appear in some patients; most patients are accompanied by pruritus symptoms.
Recent studies have shown that the pathogenic mechanism of demodex mainly includes: the mechanical stimulation, foreign body reaction, the chemical stimulation of the secretion and excretion of the demodex, which are caused by the demodex body, attract the immune cells of the organism, such as: the neutrophil, NK cell, lymphocyte and the like are involved, so that the organism generates chronic inflammatory reaction, skin inflammation symptoms such as erythema, pimple and the like are generated, in addition, the dead demodex releases inflammatory chemotactic factors in the skin to lead inflammatory cells to gather and wrap broken demodex fragments to form inflammatory granuloma tissues, and subcutaneous nodules which are difficult to self-heal clinically appear.
Disclosure of Invention
In view of the above, the present invention aims to provide the clinical application of the recombinant bovine basic fibroblast growth factor gel (trade name: bevacizine) in the drug for repairing demodex disease skin damage. The skin damage of the demodex disease is represented by subcutaneous nodules formed by erythema, pimple and inflammatory granuloma, and the demodex disease is repaired by utilizing the repair effect of the recombinant bovine basic fibroblast growth factor on mesoderm and ectoderm cells, so that the demodex disease is effectively cured clinically, and the physical and psychological burden of a patient is relieved.
Skin lesions of partial patients suffering from the Demodex mites are not repaired by recombinant bovine basic fibroblast growth factors, lymphocytes in a dermis layer gather and release inflammatory factors, skin fibrous tissues are pathologically repaired to be broken and form scars, macrophages phagocytose dead fragments of Demodex mites, epithelioid cells gather and wrap tissues around hair follicles, and lymphocytes gather to form inflammatory granuloma tissues which are difficult to self-heal. Inflammatory granuloma tissues form proliferative tissues which are difficult to repair through a long human body self-fiber repair process, and the physical and psychological health of a patient is seriously influenced. The recombinant bovine basic fibroblast growth factor is applied to clinical repair of the cutaneous lesions of the demodex diseases, the repair effect is observed, the exact repair effect is found, and the recombinant bovine basic fibroblast growth factor can obviously improve the life quality of patients and is beneficial to the physical and mental health of the patients.
The basic fibroblast growth factor has the repairing effect on burn, trauma and various chronic wounds which are difficult to heal:
basic fibroblast growth factor (bFGF), which participates in the wound repair process of various tissues in vivo, is one of important wound healing factors, and specifically, the following factors are included: chemotaxis, inflammatory cells and fibroblasts are attracted to enter a wound surface to resist inflammatory reaction; secondly, the regeneration of capillary vessels of the wound surface is promoted, and the local blood circulation is improved; direct stimulation of protein synthesis of fibroblast and extracellular matrix to form collagen and increase the tensile strength of wound surface; inducing adjacent cells to produce cell factors; fifthly, the migration, division and differentiation of the dermal cells are promoted.
bFGF can promote skin repair, thereby accelerating wound healing. A large number of basic researches and clinical tests prove that the basic fibroblast growth factor has obvious repair promoting effect on burn, trauma and various chronic wounds which are difficult to heal, and is safe, effective and free of adverse reaction. However, the application of bFGF to the repair of skin lesions of patients with demodex has not been reported.
The properties of the recombinant bovine basic fibroblast growth factor gel are as follows:
the characteristics are as follows: colorless, odorless, transparent gel.
Specification: 21000IU/5 g/branch.
Comprises the following components: the main component is recombinant bovine basic fibroblast growth factor 21000IU, which is prepared by fermenting, separating and highly purifying escherichia coli containing a high-efficiency expression bovine basic fibroblast growth factor gene. The adjuvants include protein protectant (human albumin 1 mg), gel matrix (hydroxypropyl methylcellulose and carbomer 25 mg), glycerol 110 mg, appropriate amount of pH regulator (sodium hydroxide or triethanolamine), and water for injection 5ml, and are packaged with aluminum flexible tube with 1 piece per box.
The usage and dosage are as follows: after the skin injury is cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is directly applied to the affected part at 300IU/cm22 times daily, 2 weeks is 1 course of treatment.
The recombinant bovine basic fibroblast growth factor gel is an external preparation.
And (3) storage: and (4) storing and transporting at the temperature of 2-8 ℃ in a dark place.
The validity period is as follows: 18 months old
The scheme for treating demodex diseases comprises the following steps:
1. according to the diagnostic standard of the demodex disease, the patient is diagnosed as the demodex disease, namely firstly, the head, face, neck and chest and back of the patient have erythema, pimple or nodular skin lesion with or without pruritus symptom; secondly, the skin lesion and hair follicle secretion of the patient are observed to exist demodex under a microscope;
2. cleaning Demodex mite skin lesion with clear water at moderate temperature, directly smearing the recombinant bovine basic fibroblast growth factor gel on the skin lesion, and uniformly smearing the gel at 300IU/cm22 times daily, and 2 weeks are 1 course of treatment;
3. according to the recovery condition of the skin damage of the patient, the treatment is generally carried out for 2-8 weeks, the treatment course can be properly prolonged for patients with unobvious curative effect, and the follow-up visit is carried out for 6 months after the repair is finished;
4. the healing end points are that the skin lesion erythema of the demodex patient is obviously reduced, the pimple and the nodule are smooth, and the inflammatory infiltration is obviously reduced;
5. advising patients to avoid pungent and pungent food, alcohol, excessive mental excitation and cold-hot stimulation during treatment, and keeping skin lesions clean.
Note that: the product is aseptically packaged, and the pollution of the medicine is avoided as much as possible in the operation process; ② do not put the product in high temperature or freezing environment; ③ the activity of the product can be influenced by protein denaturants such as high-concentration iodine tincture, alcohol, hydrogen peroxide, heavy metal and the like, and the product is used after being washed by normal saline after the normal debridement; used with cautions for athletes.
The mechanism of the recombinant bovine basic fibroblast growth factor gel as a medicine for repairing demodex mite disease shows that:
demodex mites (figure 2) parasitize hair follicles and sebaceous glands of humans and mammals, enter the dermis of humans, stimulate proliferation of surrounding keratinocytes and infiltrate lymphocytes around the hair follicles of the Demodex mites. The proliferated Demodex mites secrete catabolic enzymes by the salivary glands disrupting the hair follicle epithelium via limbs chelae, resulting in skin barrier disruption, inducing type IV hypersensitivity reactions, i.e., Demodex mites are attacked by phagocytes, causing granulomas centered on the hair follicle (FIG. 3 a), resulting in erythema, papules, and nodule formation. Therefore, the important point in the repair of demodex disease is to repair erythema, papules and nodules formed by inflammatory granuloma tissues at the skin lesion caused by demodex disease. The effective component in the recombinant bovine basic fibroblast growth factor gel is the recombinant bovine basic fibroblast growth factor which enters skin lesions through an external mode, penetrates into a dermis layer, starts a regulation and control mechanism of cells, promotes cell proliferation and differentiation and promotes cell repair, has the functions of nutrition, repair and regeneration on epithelial cells, fibroblasts and dermis cells, induces the formation of capillaries and improves the local circulation state, thereby repairing the skin barrier of patients with demodex and increasing the function and tolerance of the skin innate barrier; the recombinant bovine basic fibroblast growth factor has non-mitogen-like activity, attracts and chemotaxis tissue repair cells to gather to a skin lesion, releases cytokines, secretes matrix degrading enzyme, plays a role in resisting inflammation and repairing, so that local inflammatory reaction is relieved, further development of inflammation is avoided, inflammatory erythema and pimple at the skin lesion are gradually subsided, and the matrix degrading enzyme can promote formed granulation tissues or pathological fiber repair tissues to be rearranged; the recombinant bovine basic fibroblast growth factor enables fibroblasts to secrete new extracellular matrixes such as collagen, glycoprotein and the like, enables inflammation-damaged dermal layer tissues to be normally repaired, and simultaneously avoids the formation and development of inflammatory granuloma tissues.
In conclusion, the externally applied recombinant bovine basic fibroblast growth factor gel can be used for eliminating skin inflammatory erythema, pimples and nodules formed by demodex diseases, and increasing the skin barrier function and skin tolerance, so that the nodules formed by the demodex wrapped by inflammatory cells gradually recover normal tissues, and finally recover.
The invention has the advantages that:
the recombinant bovine basic fibroblast growth factor gel is used as an external preparation for repairing demodex patients, can obviously improve symptoms of erythema, pimples and nodules of the demodex patients after being externally used, increases the skin barrier function, avoids formation and further development of inflammatory granuloma tissues, obviously improves skin damage of the demodex patients in early stage or long disease course before and after repair, and has definite clinical curative effect. Clinical studies confirmed that: the recombinant bovine basic fibroblast growth factor gel has a good repair effect on demodex diseases, is simple to operate, short in medication period, high in patient compliance and high in safety, and can relieve physical and psychological pains of patients by eliminating skin lesions of the patients and eliminating erythema and pimple nodules. Opens up a new treatment way for the recombinant bovine basic fibroblast growth factor gel.
Drawings
FIG. 1 is the appearance of recombinant bovine basic fibroblast growth factor gel (Beading) drug.
FIG. 2 is a diagram of demodex observed under a microscope.
FIG. 3a is a histopathological view of granuloma tissue structures in the pre-repair dermis as observed under a microscope;
FIG. 3b is a histopathological image of granuloma tissue structure observed under a microscope after 1 month of repair;
FIG. 3c is a histopathological image of granuloma tissue structure observed under a microscope after 2 months after repair;
FIG. 4a is a representation of a lesion before repair in a horse of a patient with demodex in accordance with the present invention;
FIG. 4b is a graph showing the skin damage of demodex patients after 12 weeks of repair.
FIG. 5a is a representation of a lesion before a certain repair in a demodex patient according to the invention;
FIG. 5b is a graph showing the skin damage of demodex patients after a certain period of repair for 12 weeks.
FIG. 6a is a representation of a lesion before repair in plum for demodex patients according to the present invention;
FIG. 6b is a representation of the skin lesion of a demodex patient of plum after 8 weeks of repair according to the present invention.
FIG. 7a is a representation of a lesion before a certain repair on a demodex patient according to the present invention;
FIG. 7b is a graph showing the skin lesions of demodex patients repaired for 4 weeks according to the present invention.
Detailed Description
The effect of the recombinant bovine basic fibroblast growth factor as a medicine for repairing demodex mites is illustrated by taking a typical case as an example and combining the attached drawings:
typical case 1: a patient in a dermatology clinic of our hospital is diagnosed with a madam male in 28 years and 11 months in 2018 due to 'erythema on face, neck, chest and back and papular nodule in 3 months' (fig. 4 a), and feels that the skin of the face, neck and chest and back is dry and is accompanied with mild symptomsAnd (4) pruritus. The existence of demodex is observed in skin lesions and hair follicle secretions of patients under a microscope, and the demodex disease is diagnosed, and the skin lesions of the patients are scattered on the face, the neck and the chest and back and show erythema papule nodules with the diameter of about 0.3-2 cm. In the treatment process, after skin lesions are cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is added at 300IU/cm2Directly applied to the affected part, and the patients are ordered to take the medicine for external application 1 time respectively in the morning and evening. When the 4 th week of repair is carried out, the red spots on the skin lesions of the chest, the back and the face and the neck of the patient turn light in color, the inflammatory infiltration is not obvious, the local papule is more smooth than before, and the nodules formed by the inflammatory granuloma are slightly smooth; when the 8 th week of repair is performed, the erythema at the skin lesions of the chest, the back and the face and the neck of the patient is obviously lightened compared with the former, the papules are completely leveled, part of nodules are obviously leveled compared with the former, and the pruritus at the skin lesions is obviously relieved; at week 12 of repair (fig. 4 b), the patient's facial neck and chest back skin lesions healed and the subcutaneous nodules formed by inflammatory granulomas apparently subsided smoothly. The skin lesion does not relapse after 6 months of follow-up. Comparing fig. 4a with fig. 4b, it can be seen that: the skin damage of the patient is obviously improved, and the erythema papule nodule obviously subsides repeatedly.
Typical case 2: when a certain woman is in 49 years old and is in a diagnosis of a dermatology clinic of our hospital in 2019 for 1 month because of the diffuse erythema pimple nodule on the face of the woman in 2 months (figure 5 a), the existence of the demodex is observed under an objective lens for secreting skin lesions and hair follicles, the demodex disease is diagnosed, and the skin lesions of the patient are diffusely distributed on the face and are expressed as the erythema pimple nodule with the diameter of about 0.1-1.5 cm. In the treatment process, after skin lesions are cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is added at 300IU/cm2Directly applied to the affected part, and the patients are ordered to take the medicine for external application 1 time respectively in the morning and evening. At the 4 th week of repair, the diffuse flush erythema area of the patient face is retracted, the color is slightly lighter than that of the previous one, the local papule is more smooth than that of the previous one, and nodules formed by inflammatory granuloma have no obvious change; after 8 weeks of repair, the red spot color of the facial skin damage of the patient is obviously lighter than that of the former facial skin damage, the inflammatory infiltration phenomenon is obviously better, the papule is obviously better than that of the former facial skin damage, and the nodule is slightly better than that of the former facial skin damage; after 12 weeks of repair, the patient had obvious regression of facial erythema, smooth papules, and obvious recovery of subcutaneous nodules formed by granuloma more than before, and the patient had self-perceptionThe face is more delicate than the front (fig. 5 b). The skin lesion does not relapse after 6 months of follow-up. As can be seen from the comparison between the figure 5a and the figure 5b, the skin damage of the patient is obviously improved, the erythema papule nodule obviously subsides smoothly, and the recombinant bovine basic fibroblast growth factor gel has the effect of repairing the skin damage of the demodex disease.
Typical case 3: when a certain plum is in 20 years old and 12 months in 2018, the patient is diagnosed with the demodex disease because of the fact that the patient is in outpatient service in dermatology of our hospital and the existence of demodex is observed under an objective lens for secreting skin lesions and hair follicles, the skin lesions of the patient are mainly distributed around eyes at two sides and are expressed as the pimples with the diameter of about 1-1.5 cm and about 0.1cm on the basis of erythema, the patient self-complaints the pruritus symptom, and during treatment, after the skin lesions are cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is treated with 300IU/cm2Directly applied to the affected part, and the patients are ordered to take the medicine for external application 1 time respectively in the morning and evening. After 2 weeks of repair, the color of the erythema of the skin damage around the eyes of the patient is changed to be light, the retraction of the area of the erythema around the eyes can be observed, the inflammatory infiltration condition is reduced, the swelling is relieved, and the local papule is more smooth and better than the former one; after the 4 th week of repair, the erythema of the patient turns to be light around the eyes, no obvious inflammatory infiltration condition exists, the pimple obviously improves better than before, the medicine is continuously taken for 4 weeks, the skin damage and the skin damage are healed (figure 6 b), no obvious erythema pimple exists around the eyes, the swelling is obviously subsided, and the subjective pruritus symptom of the patient is obviously relieved. The skin lesion does not relapse after 6 months of follow-up. As can be seen from FIGS. 6a to 6b, after the skin lesion of the patient is cured, the skin lesion of the demodex disease is obviously improved, the skin lesion of the patient is obviously improved, and the erythema pimple is obviously reduced.
Typical case 4: when a certain woman in the age of 13 years is diagnosed in an outpatient clinic of the dermatology department of our hospital for 2 weeks (figure 7 a) of 2019 due to the fact that facial erythema with itching is observed under an objective lens for skin damage and hair follicle secretion, the disease is diagnosed as demodex disease, skin damage of a patient is scattered on the face and is shown as erythema with the diameter of about 1-1.5 cm, the patient self-complaints of the obvious itching symptom, during treatment, after the skin damage is cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is applied with 300IU/cm2Directly applied to the affected part, and the patients are ordered to take the medicine for external application 1 time respectively in the morning and evening. After week 2 of repair, the patient's faceThe erythema of the skin lesion is obviously reduced compared with the prior erythema, the pruritus symptom is obviously relieved compared with the prior erythema, after 4 weeks of repair, the skin lesion of the patient is healed, no obvious inflammatory erythema is seen, and the pruritus symptom is not found. Following 6 months, the skin lesions did not recur (fig. 7 b). As can be seen from FIGS. 7a to 7b, the skin lesions of the patients were improved and the erythema was reduced, indicating that the recombinant bovine basic fibroblast growth factor gel produced a good effect in repairing the skin lesions of demodex diseases.
The invention further elaborates the restoration of demodex disease of the recombinant bovine basic fibroblast growth factor medicine through clinical tests:
the invention carries out statistical analysis on the repair result of demodex patients:
(1) clinical data: 130 demodex patients subjected to reparative treatment in a dermatology clinic of a hospital during 2018 from 1 month to 2019 from 4 months are selected, wherein 81 female patients (62.31%), 49 male patients (37.69%), the age is 18-64 years, the average (30.17 +/-4.58) years, the course of disease is 0.11-13 years, and the average (3.04 +/-4.93) years. All patients use the recombinant bovine basic fibroblast growth factor gel to be locally smeared on skin lesions, 300IU/cm22 times a day, 2 weeks is 1 course of treatment, and the course of treatment can be prolonged for patients with unobvious curative effect.
(2) Reagents and materials: recombinant bovine basic fibroblast growth factor 21000IU/5 g/count (manufacturing enterprise: Zhuhai Yisheng biopharmaceutical Co., Ltd.)
(3) Grouping standard: inclusion criteria were: clinical presentation was consistent with demodex disease and facial demodex microscopic positive (figure 2). Exclusion criteria: pregnant and lactating women; patients with serious primary diseases such as cardiovascular diseases, liver diseases, kidney diseases, hemopoietic diseases, and the like; patients with psychosis and tumor; patients who had been diagnosed and treated for demodex disease; patients who have been allergic to recombinant bovine basic fibroblast growth factor. All patients enrolled signed informed consent.
(4) The treatment method comprises the following steps: after the skin lesion is cleaned by clear water with moderate temperature, the recombinant bovine basic fibroblast growth factor gel is directly smeared on the skin lesion at 300IU/cm22 times a day, 2 weeks is 1 treatment course, and the curative effect is not obviousThe treatment course is properly prolonged, and the follow-up visit is 6 months after the repair is finished.
(5) Observation indexes and therapeutic effect evaluation standards: all patients are scored for skin damage by fixed doctors before and after the gel repair of the recombinant bovine basic fibroblast growth factor, indexes comprise erythema, pimples and nodules, and all indexes are scored according to a four-level scoring method: no point of 0, a lightness meter of 1, a moderate point of 2 and a severe point of 3.
Efficacy index = (before repair-after repair) total integral/before repair total integral × 100%.
And (3) curing: the curative effect index is more than or equal to 90 percent, and the skin damage is basically subsided in clinical manifestation;
the effect is shown: the curative effect index is more than or equal to 60 percent and less than 90 percent, and most of the skin damage is removed;
improvement: the curative effect index is more than or equal to 30 percent and less than 60 percent, and the skin damage is reduced to some extent;
and (4) invalidation: the curative effect index is less than 30%, and the skin damage is not obviously improved.
The total effective rate = (cure + significant effect)/the total people number x 100%.
(6) Results
TABLE I rbFGF 8 weeks after repair each index condition table (Unit: human)
| Erythema (n = 130) | Papule (n = 49) | Node (n = 29) | |
| Cure of disease | 104 | 29 | 17 |
| Show effect | 17 | 13 | 4 |
| Improvement of life | 8 | 4 | 5 |
| Invalidation | 1 | 2 | 3 |
Second, the total effective rate (unit:%) of rbFGF for repairing demodex patients
| Erythema | Pimple | Node (B) |
| 93.07 | 85.71 | 72.41 |
The total effective rates of erythema, pimple and nodule of the recombination bovine basic fibroblast growth factor repairing patient are 93.07%, 85.71% and 72.41% respectively by observing the indexes, therefore, the recombination bovine basic fibroblast growth factor gel can make the demodex disease show that the skin damage of the erythema, the pimple and the nodule is obviously improved, the recombination bovine basic fibroblast growth factor can promote the repair and regeneration of epithelial cells, dermal cells, fibroblasts, vascular endothelial cells and other cells, make the skin damage of the patient disappear, the erythema and the pimple nodule subside smoothly, and avoid the formation and further development of inflammatory granuloma, and the reparative treatment period is short and the side effect is small.
From clinical applications, we recognize that: demodex mite disease is a common disease. The research shows that: demodex mite disease is a genetically predisposed skin disease mediated by a specific immune function deficiency or reduction in the host. The barrier function of the skin is damaged through mechanical stimulation and inflammation mediation, and then the formation of skin lesions such as erythema, pimples, nodules and the like is initiated. In addition, the skin temperature is increased, the oily or mixed skin and the face are poor in cleaning condition, the face is thick in makeup, and other inducements cause the change of the skin microenvironment and the stimulation of the proliferation of the demodex, so that the occurrence of the demodex diseases is caused. The recombinant bovine basic fibroblast growth factor promotes cell proliferation and differentiation and promotes cell repair, and has the functions of nutrition, repair and regeneration on epithelial cells, fibroblasts and dermal cells, so that the skin barrier of patients with demodex is repaired, and the function and tolerance of the skin innate barrier are increased; the recombinant bovine basic fibroblast growth factor has non-mitogen-like activity, and chemotactic tissue repair cells are gathered to a rash part to play a role in resisting inflammation and repairing, so that local inflammatory reaction is relieved, further development of inflammation is avoided, formation and development of inflammatory granuloma tissues are avoided, the clinical junction is improved, and hypertrophic skin damage is avoided. The invention uses the external gel of the recombinant bovine basic fibroblast growth factor, which is used for repairing patients with demodex, the symptoms of erythema, pimple and nodule can be obviously improved after the external gel of the recombinant bovine basic fibroblast growth factor is externally used, the patients with demodex are in early stage or late stage, the recombinant bovine basic fibroblast growth factor has obvious repairing effect on skin damage of the patients, aiming at inflammatory granuloma, the histopathology before repair is observed from the histopathology angle to show that the epidermis is hyperplastic and thick, the superficial layer of dermis can be seen to be granuloma tissues formed by epithelioid cells, multinuclear giant cells and mononuclear cells, and the infiltration of lymphocytes can be seen at the periphery (figure 3 a); the granuloma tissue is reduced earlier and the hyperplastic epidermis is better after 1 month of repair by the recombinant bovine basic fibroblast growth factor (figure 3 b); the granuloma tissue is obviously regressed before 2 months after the repair of the bovine basic fibroblast growth factor, and the epidermis is recovered to be normal before the repair, so that the exact clinical curative effect is obtained (figure 3 c). Clinical studies confirmed that: the recombinant bovine basic fibroblast growth factor has a good repair effect on demodex diseases, high patient compliance and few adverse reactions, and can be popularized in a large range.
Claims (1)
1. In clinical experiments, the recombinant bovine basic fibroblast growth factor gel is externally applied to the skin lesion of a demodex patient twice a day with the dosage of 300IU/cm22 weeks is 1 course of treatment, and the treatment lasts for 2-8 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911086633.8A CN110624102A (en) | 2019-11-08 | 2019-11-08 | Clinical application of bevacizine as medicine for repairing demodex disease skin damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911086633.8A CN110624102A (en) | 2019-11-08 | 2019-11-08 | Clinical application of bevacizine as medicine for repairing demodex disease skin damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110624102A true CN110624102A (en) | 2019-12-31 |
Family
ID=68979266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911086633.8A Pending CN110624102A (en) | 2019-11-08 | 2019-11-08 | Clinical application of bevacizine as medicine for repairing demodex disease skin damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110624102A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023015341A1 (en) * | 2021-08-09 | 2023-02-16 | The University Of Western Australia | Compositions and methods for wound healing |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106551929A (en) * | 2016-11-05 | 2017-04-05 | 罗洋 | New application of the Ornidazole in treatment acne rosacea medicine |
| CN106563121A (en) * | 2016-11-05 | 2017-04-19 | 罗洋 | Application of recombinant bovine basic fibroblast growth factor gel in repairing acne rosacea skin lesion |
| CN109700805A (en) * | 2018-12-29 | 2019-05-03 | 罗洋 | Ornidazole is as controlling application of the demodicidosis drug in clinic |
| CN110278919A (en) * | 2019-07-30 | 2019-09-27 | 罗洋 | A method of building vermiform mite causes acne rosacea sample skin lesion animal model |
-
2019
- 2019-11-08 CN CN201911086633.8A patent/CN110624102A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106551929A (en) * | 2016-11-05 | 2017-04-05 | 罗洋 | New application of the Ornidazole in treatment acne rosacea medicine |
| CN106563121A (en) * | 2016-11-05 | 2017-04-19 | 罗洋 | Application of recombinant bovine basic fibroblast growth factor gel in repairing acne rosacea skin lesion |
| CN109700805A (en) * | 2018-12-29 | 2019-05-03 | 罗洋 | Ornidazole is as controlling application of the demodicidosis drug in clinic |
| CN110278919A (en) * | 2019-07-30 | 2019-09-27 | 罗洋 | A method of building vermiform mite causes acne rosacea sample skin lesion animal model |
Non-Patent Citations (2)
| Title |
|---|
| YANG LUO等: "Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single‑blind and vehicle‑controlled study", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| YANG LUO等: "Treatment of mites folliculitis with an ornidazole-based sequential therapy A randomized trial", 《MEDICINE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023015341A1 (en) * | 2021-08-09 | 2023-02-16 | The University Of Western Australia | Compositions and methods for wound healing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104667335A (en) | Recombinant human-derived collagen product for skin barrier function or haemorrhoids and preparation method | |
| Tamburino et al. | The role of nanofat grafting in vulvar lichen sclerosus: a preliminary report | |
| CN1251530A (en) | Use of substaces having oxytocin activity for preparation of medicaments for wound healing | |
| KR102048119B1 (en) | Kit for prevention of skin aging and a system for skin beauty | |
| KR20050109969A (en) | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin | |
| EA032439B1 (en) | Compositions and methods for treating surface wounds | |
| US10350247B2 (en) | Pharmaceutical composition for preventing, treating, and curing psoriasis including snail slime, chamomile, and honey | |
| Zheng et al. | Materials selection for the injection into vaginal wall for treatment of vaginal atrophy | |
| CN110624102A (en) | Clinical application of bevacizine as medicine for repairing demodex disease skin damage | |
| US20240082134A1 (en) | Compositions and methods of use for treatment or improvement of the condition and appearance of skin | |
| US20170281690A1 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| Zawrzykraj et al. | The effect of chemotherapy and radiotherapy on stem cells and wound healing. Current perspectives and challenges for cell-based therapies | |
| CN112933214A (en) | Composition for promoting wound healing | |
| CN106563121B (en) | BFGF bovine basic fibroblast growth factor gel is repairing the application in acne rosacea skin lesion | |
| Chandra et al. | Potential application of Wharton’s jelly-derived mesenchymal stem cells conditioned medium (WJMSCs-CM) on delayed wound healing: a case report | |
| KR20200044434A (en) | Composition for treating intractable ulcer comprising substance P | |
| CN112915100A (en) | A composition for preventing and treating scar | |
| CN101057823B (en) | Composite biological preparation with antisenility and beautifying function | |
| RU2805144C1 (en) | Recombinant angiogenin in cosmetic and pharmaceutical compositions | |
| RU2811255C1 (en) | Method of treating rosacea conglobate by points | |
| RU2811254C1 (en) | Method of treating erythematotelangiectatic subtype of rosacea by points | |
| US20240016893A1 (en) | Compositions and methods for treating wounds | |
| RU2814362C1 (en) | Method of treating rosacea with solid persistent oedema by points | |
| CN114344466B (en) | Use of PCSK9 inhibitors for the preparation of products for the treatment of keratinization disorders | |
| CN1330371C (en) | Recombinant human epidermal growth factor compound biological agent and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191231 |
|
| RJ01 | Rejection of invention patent application after publication |